Finance entity
Every one of those 1 sits in a single category, markets. Opdivo is most often covered alongside AstraZeneca, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Finance story that mention Opdivo, all published on August 2, 2026.
Last mentioned: Aug 2, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, markets. Opdivo is most often covered alongside AstraZeneca, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Finance story that mention Opdivo, all published on August 2, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 17 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Opdivo. Shared-story counts are live from our verified record — not editorial picks.
The speculative $400 billion merger would rank among the largest ever, offering BMS stockholders an exit from patent headwinds and giving AZN a US listing boost. However, financing structure and antitrust hurdles present major risks.
Opdivo is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
